IS6986A - Lyfjasamsetning í vökvaformi - Google Patents

Lyfjasamsetning í vökvaformi

Info

Publication number
IS6986A
IS6986A IS6986A IS6986A IS6986A IS 6986 A IS6986 A IS 6986A IS 6986 A IS6986 A IS 6986A IS 6986 A IS6986 A IS 6986A IS 6986 A IS6986 A IS 6986A
Authority
IS
Iceland
Prior art keywords
pharmaceutical composition
liquid pharmaceutical
liquid
composition
pharmaceutical
Prior art date
Application number
IS6986A
Other languages
English (en)
Other versions
IS2428B (is
Inventor
Mahesh Kulkarni Neema
Schneider Michael
Bernard Silbering Steven
Richard Meyer-Wonnay Hans
Sanii-Yahyai Nahid
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26968180&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS6986(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of IS6986A publication Critical patent/IS6986A/is
Publication of IS2428B publication Critical patent/IS2428B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
IS6986A 2001-05-25 2003-10-09 Fljótandi lyfjasamsetning IS2428B (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29383201P 2001-05-25 2001-05-25
US34373301P 2001-10-25 2001-10-25
PCT/IB2002/001500 WO2002094220A1 (en) 2001-05-25 2002-04-29 Liquid pharmaceutical composition

Publications (2)

Publication Number Publication Date
IS6986A true IS6986A (is) 2003-10-09
IS2428B IS2428B (is) 2008-10-15

Family

ID=26968180

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6986A IS2428B (is) 2001-05-25 2003-10-09 Fljótandi lyfjasamsetning

Country Status (44)

Country Link
US (2) US20020198261A1 (is)
EP (1) EP1395242B1 (is)
JP (1) JP2004534764A (is)
KR (1) KR100582963B1 (is)
CN (1) CN100346779C (is)
AP (1) AP1815A (is)
AR (1) AR033922A1 (is)
AT (1) ATE334656T1 (is)
AU (1) AU2002258026B2 (is)
BG (1) BG108376A (is)
BR (1) BR0209973A (is)
CA (1) CA2446574C (is)
CR (1) CR7150A (is)
CY (1) CY1105147T1 (is)
CZ (1) CZ299755B6 (is)
DE (1) DE60213592T2 (is)
DK (1) DK1395242T3 (is)
DO (1) DOP2002000403A (is)
EA (1) EA008087B1 (is)
EE (1) EE200300587A (is)
EG (1) EG24078A (is)
ES (1) ES2265040T3 (is)
GE (1) GEP20053620B (is)
HK (1) HK1062646A1 (is)
HR (1) HRP20030833B1 (is)
HU (1) HUP0401366A2 (is)
IL (1) IL158359A0 (is)
IS (1) IS2428B (is)
MA (1) MA27026A1 (is)
MX (1) MXPA03009392A (is)
MY (1) MY128615A (is)
NO (1) NO20035200D0 (is)
NZ (1) NZ529173A (is)
OA (1) OA12604A (is)
PA (1) PA8545901A1 (is)
PE (1) PE20030087A1 (is)
PL (1) PL366384A1 (is)
PT (1) PT1395242E (is)
RS (1) RS87203A (is)
SI (1) SI1395242T1 (is)
SK (1) SK286227B6 (is)
SV (1) SV2003001053A (is)
WO (1) WO2002094220A1 (is)
ZA (1) ZA200308393B (is)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100491282B1 (ko) 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
EP1545491A1 (en) * 2002-08-15 2005-06-29 Pfizer Limited Therapeutic use of fused bicyclic or tricyclic amino acids
NZ540591A (en) * 2002-12-13 2008-03-28 Warner Lambert Co Pregabalin derivatives for the treatment of fibromyalgia and other disorders
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
AU2003301184A1 (en) * 2002-12-20 2004-07-22 Dynogen Pharmaceuticals Inc METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING Alpha2Delta SUBUNIT CALCIUM CHANNEL MODULATORS
US7169812B2 (en) * 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
AU2004271800A1 (en) * 2003-09-12 2005-03-24 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
CA2540052C (en) * 2003-10-08 2012-04-10 Mallinckrodt Inc. Methylphenidate solution and associated methods of administration and production
US20050090548A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of epilepsy
US20050090549A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of pain
EP1543831A1 (en) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Pregabalin composition
DE102004015752B4 (de) * 2004-03-31 2007-04-05 Christian-Albrechts-Universität Zu Kiel Verwendung von Gabapentin-Laktam zur Behandlung renaler Erkrankungen
US20080112893A1 (en) * 2004-10-14 2008-05-15 Arai Jun-Ichiro Atmosphere Modifying Method and Spray Agent and Spray Device Used in the Same
CA2618474A1 (en) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Compounds for treating alzheimer's disease
CA2618481A1 (en) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Compounds for treating alzheimer's disease
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
EP2246044A1 (en) * 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Paediatric solutions comprising a beta-blocker
HU230031B1 (hu) 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
TR201005241A1 (tr) * 2010-05-25 2012-01-23 Sanovel �La� San. Ve T�C. A.�. Kontrollü salım sağlayan pregabalin solüsyon formülasyonu.
EP2923694B1 (en) * 2014-03-27 2018-11-14 Sanovel Ilac Sanayi ve Ticaret A.S. Oral liquid pharmaceutical solution of gabapentin
CN104940930A (zh) * 2015-05-31 2015-09-30 黑龙江佰彤儿童药物研究有限公司 一种治疗儿童癫痫药物口服乳剂及其制备方法
WO2018167628A1 (en) 2017-03-13 2018-09-20 Ftf Pharma Private Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
EP3668508A1 (en) 2017-08-19 2020-06-24 FTF Pharma Private Limited An oral pharmaceutical composition comprising zonisamide and process of preparation thereof
WO2019186515A1 (en) * 2018-03-30 2019-10-03 Ftf Pharma Private Limited Liquid pharmaceutical compositions of antiepileptic drugs
US12083222B2 (en) 2018-08-18 2024-09-10 Oncosol Limited Chemotherapeutic pharmaceutical suspension for oral dosage
WO2020039263A2 (en) 2018-08-18 2020-02-27 Ftf Pharma Private Limited Pharmaceutical suspension for oral dosage
US20220175707A1 (en) 2019-03-26 2022-06-09 Orion Corporation Pregabalin formulations and use thereof
JPWO2022168968A1 (is) * 2021-02-05 2022-08-11
CN118139617A (zh) * 2021-08-31 2024-06-04 艾维恩制药有限公司 稳定的加巴喷丁粉体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294520B1 (en) * 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
EP1077692B1 (en) * 1998-05-15 2004-07-28 Warner-Lambert Company LLC Amino acid stabilized gabapentin and pregabalin preparations and process for preparing the same
PT1337271E (pt) * 2000-11-30 2005-01-31 Pfizer Prod Inc Combinacao de agonistas de gaba e inibidores de sorbitol desidrogenase

Also Published As

Publication number Publication date
ZA200308393B (en) 2005-04-26
HRP20030833B1 (en) 2007-04-30
CA2446574A1 (en) 2002-11-28
MY128615A (en) 2007-02-28
MA27026A1 (fr) 2004-12-20
PL366384A1 (en) 2005-01-24
KR100582963B1 (ko) 2006-05-24
NO20035200L (no) 2003-11-24
CA2446574C (en) 2008-04-01
HK1062646A1 (en) 2004-11-19
CR7150A (es) 2004-02-23
CY1105147T1 (el) 2010-03-03
RS87203A (en) 2006-10-27
US7256216B2 (en) 2007-08-14
BG108376A (bg) 2005-04-30
SI1395242T1 (en) 2006-10-31
SK14112003A3 (sk) 2004-08-03
CZ20033066A3 (cs) 2004-08-18
PA8545901A1 (es) 2003-09-05
EA200301152A1 (ru) 2004-04-29
CZ299755B6 (cs) 2008-11-12
AR033922A1 (es) 2004-01-07
AU2002258026B2 (en) 2007-08-02
IS2428B (is) 2008-10-15
PE20030087A1 (es) 2003-02-14
GEP20053620B (en) 2005-09-26
US20040072904A1 (en) 2004-04-15
EP1395242A1 (en) 2004-03-10
KR20040003006A (ko) 2004-01-07
SK286227B6 (sk) 2008-05-06
BR0209973A (pt) 2004-04-06
CN100346779C (zh) 2007-11-07
HUP0401366A2 (hu) 2004-11-29
DE60213592T2 (de) 2007-08-09
OA12604A (en) 2006-06-08
MXPA03009392A (es) 2004-01-29
PT1395242E (pt) 2006-11-30
SV2003001053A (es) 2003-03-18
DE60213592D1 (de) 2006-09-14
ATE334656T1 (de) 2006-08-15
AP1815A (en) 2008-01-04
NO20035200D0 (no) 2003-11-24
WO2002094220A1 (en) 2002-11-28
HRP20030833A2 (en) 2004-08-31
EA008087B1 (ru) 2007-02-27
EE200300587A (et) 2004-02-16
NZ529173A (en) 2005-07-29
DK1395242T3 (da) 2006-10-30
EP1395242B1 (en) 2006-08-02
ES2265040T3 (es) 2007-02-01
JP2004534764A (ja) 2004-11-18
IL158359A0 (en) 2004-05-12
EG24078A (en) 2008-05-11
DOP2002000403A (es) 2002-11-30
CN1509165A (zh) 2004-06-30
AP2003002907A0 (en) 2003-12-31
US20020198261A1 (en) 2002-12-26

Similar Documents

Publication Publication Date Title
IS6986A (is) Lyfjasamsetning í vökvaformi
FI20011478A0 (fi) Farmaseuttinen koostumus
NO20033384D0 (no) Farmasöytisk formulering
NO20025450L (no) Ny farmasöytisk sammensetning
DK1524266T3 (da) Farmaceutisk sammensætning
NO20033785D0 (no) Farmasöytisk formulering
EE05020B1 (et) Glburiidi ravimkoostis
DK1458377T3 (da) Farmaceutiske sammensætninger indeholdende tegaserod
IS7051A (is) Lyfjasamsetningar
NO20035627D0 (no) Farmasöytisk formulering
FI20022128A (fi) Farmaseuttinen koostumus
DK1425005T3 (da) Farmaceutisk sammensætning indeholdende lumiracoxib
ATE350016T1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
NO20041485L (no) Farmasoytisk formulering omfattende (R)-bicalutamid
DE10291905D2 (de) Pharmazeutische Zusammensetzung
ATE350029T1 (de) Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
NO20033073L (no) Farmasöytisk sammensetning inneholdende citalopram
NO20015534D0 (no) Farmasöytisk blandeapparat
DE10107261B4 (de) Pharmazeutische Zusammensetzung
FI20012242A0 (fi) Uudet farmaseuttiset yhdisteet
FI5468U1 (fi) Farmaseuttinen koostumus
SE0100847D0 (sv) Novel pharmaceutical composition
NO20041236L (no) Farmasoytisk formulering
DK1307264T3 (da) Hidtil ukendt farmaceutisk præparat
SE0101326D0 (sv) Pharmaceutical formulation